PACB has been among the more volatile names in the life-sciences and genomics tools sector, trading in a wide range as investors weigh a fast-expanding artificial-intelligence data story against ongoing losses and cash consumption. After an eight-session advance that more than doubled the share price around late September into early October, the stock retraced a large portion of those gains and settled back into the low single digits of movement over the trailing month. The result is a small-cap equity whose near-term price action remains heavily driven by sentiment around AI-enabled drug discovery and clinical long-read sequencing, rather than by profitability metrics alone.
PacBio designs, develops, and manufactures high-accuracy long-read DNA and RNA sequencing systems, consumables, and related services. Its core platforms include the Revio, Vega, and Sequel instruments, which use Single Molecule, Real-Time (SMRT) technology and the company's HiFi sequencing chemistry to read much longer stretches of genetic material than traditional short-read systems. This capability is especially valued for detecting structural variants, resolving complex genomic regions, and generating full-length transcript data.
The company competes across the broader sequencing market with firms such as Illumina (ILMN) while differentiating on long-read accuracy and read length. Growth is increasingly tied to three areas: adoption of the newer SPRQ-Nx chemistry, expansion of clinical whole-genome sequencing, and demand for biodata used to train AI models. Investors follow PACB for its positioning at the intersection of genomics and artificial intelligence, balanced against a still-loss-making operating profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
PacBio's most recent quarterly results showed revenue of $40.6 million, up about 6% from a year earlier, as instrument revenue rose while consumables revenue dipped amid customer inventory drawdowns and a transition to multi-use workflows. Management narrowed its full-year 2026 revenue outlook to a range of $155 million to $160 million and lowered its non-GAAP operating-expense forecast, reflecting restructuring savings while maintaining a 2028 cash-flow breakeven target.
The SPRQ-Nx chemistry has become a central catalyst. It now represents more than half of Revio consumables revenue, and roughly two-thirds of the installed Revio base had upgraded software by the end of the quarter. PacBio expects annualized Revio consumables pull-through of $200,000 to $225,000 in 2026 before returning to a $225,000 to $250,000 range in 2027 as sample elasticity improves.
AI-related partnerships have also drawn investor attention. PacBio announced an agreement to generate full-length RNA data from more than 10,000 samples for TychoBio, which will use the data to train models for RNA-based drug discovery, building on earlier work with Basecamp Research's Trillion Gene Atlas and a collaboration with Verily Health on AI-ready genomic and clinical datasets. On the clinical side, GeneDx (WGS) disclosed plans to add long-read whole-genome sequencing, and Berry Genomics added 10 Revio systems for a rare-disease program. Separately, PacBio resolved litigation through a patent-license agreement with Personal Genomics of Taiwan.
These developments fueled the sharp rally, while profit-taking and persistent concerns about cash burn and academic funding constraints contributed to the subsequent pullback.
Looking ahead, the key variables for PACB include the pace of SPRQ-Nx adoption across the installed base and whether consumables pull-through recovers toward management's 2027 target range. Continued expansion of clinical sequencing, particularly in Europe and through deals such as the GeneDx long-read initiative, will be important for durable growth. Investors will also monitor the commercial translation of AI-related data partnerships, which management has cautioned will take time to convert into meaningful revenue.
Financial execution remains central. PacBio ended the third quarter with about $199 million in cash and has guided toward lower cash burn in the fourth quarter, with a stated goal of reaching cash-flow breakeven in 2028. Macroeconomic and funding conditions, competition across the sequencing market, and the company's ability to sustain gross margin will also shape the outlook. These are forward-looking considerations rather than guarantees of performance.
In my regular research, I turn to Tickeron’s Trending AI Robots to review automated strategies that align with stocks like PACB. The page highlights top-performing bots from a broad universe, letting users compare approaches by timeframe, performance, and risk profile. It serves as a practical starting point when evaluating systematic options for the current market environment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 50-day moving average for PACB moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in 226 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 109 of 138 cases where PACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The 10-day RSI Indicator for PACB moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 27 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In 74 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 38 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
PACB moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
PACB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: PACB's P/B Ratio (-21.104) is slightly lower than the industry average of (4.142). P/E Ratio (-5.369) is within average values for comparable stocks, (3.291). PACB's Projected Growth (PEG Ratio) (180.110) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of sequencing system products to help scientists to resolve genetically complex problems
Industry MedicalNursingServices